# Single-cell profiling of surface glycosphingolipids opens a new dimension for deconvolution of breast cancer intratumoral heterogeneity and phenotypic plasticity

**Authors:** Jiřina Procházková, Radek Fedr, Barbora Hradilová, Barbora Kvokačková, Josef Slavík, Ondrej Kováč, Miroslav Machala, Pavel Fabian, Jiří Navrátil, Simona Kráčalíková, Monika Levková, Petra Ovesná, Jan Bouchal, Karel Souček

PMC · DOI: 10.1016/j.jlr.2024.100609 · 2024-07-30

## TL;DR

This study uses single-cell analysis to explore how surface lipids in breast cancer cells reflect tumor diversity and cell plasticity.

## Contribution

A 12-color spectral flow cytometry panel was developed to detect glycosphingolipid epitopes and cell markers at the single-cell level in breast cancer.

## Key findings

- Gb3 levels are higher in epithelial cells, while GD2 is elevated in mesenchymal cells.
- Surface heterogeneity in GSL epitopes was observed in breast cancer primary tumors.
- Phenotype-dependent changes in GSL profiles were found between epithelial and stromal cells.

## Abstract

Glycosylated sphingolipids (GSLs) are a diverse group of cellular lipids typically reported as being rare in normal mammary tissue. In breast cancer (BCa), GSLs have emerged as noteworthy markers associated with breast cancer stem cells, mediators of phenotypic plasticity, and contributors to cancer cell chemoresistance. GSLs are potential surface markers that can uniquely characterize the heterogeneity of the tumor microenvironment, including cancer cell subpopulations and epithelial–mesenchymal plasticity (EMP). In this study, mass spectrometry analyses of the total sphingolipidome in breast epithelial cells and their mesenchymal counterparts revealed increased levels of Gb3 in epithelial cells and significantly elevated GD2 levels in the mesenchymal phenotype. To elucidate if GSL-related epitopes on BCa cell surfaces reflect EMP and cancer status, we developed and rigorously validated a 12-color spectral flow cytometry panel. This panel enables the simultaneous detection of native GSL epitopes (Gb3, SSEA1, SSEA3, SSEA4, and GD2), epithelial–mesenchymal transition markers (EpCAM, TROP2, and CD9), and lineage markers (CD45, CD31, and CD90) at the single-cell level. Next, the established panel was used for the analysis of BCa primary tumors and revealed surface heterogeneity in SSEA1, SSEA3, SSEA4, GD2, and Gb3, indicative of native epitope presence also on non-tumor cells. These findings further highlighted the phenotype-dependent alterations in GSL surface profiles, with differences between epithelial and stromal cells in the tumor. This study provides novel insights into BCa heterogeneity, shedding light on the potential of native GSL-related epitopes as markers for EMP and cancer status in fresh clinical samples. The developed single-cell approach offers promising avenues for further exploration.

## Linked entities

- **Proteins:** EPCAM (epithelial cell adhesion molecule), TACSTD2 (tumor associated calcium signal transducer 2), CD9 (CD9 molecule), PTPRC (protein tyrosine phosphatase receptor type C), PECAM1 (platelet and endothelial cell adhesion molecule 1), THY1 (Thy-1 cell surface antigen)
- **Chemicals:** Gb3 (PubChem CID 5353448), SSEA1 (PubChem CID 643990), SSEA3 (PubChem CID 53262342), GD2 (PubChem CID 11966234)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** EPCAM (epithelial cell adhesion molecule) [NCBI Gene 4072] {aka Ber-Ep4, BerEp4, DIAR5, EGP-2, EGP314, EGP40}, CD9 (CD9 molecule) [NCBI Gene 928] {aka BTCC-1, DRAP-27, MIC3, MRP-1, TSPAN-29, TSPAN29}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CTSA (cathepsin A) [NCBI Gene 5476] {aka BSVD6, GLB2, GSL, NGBE, PPCA, PPGB}, FUT4 (fucosyltransferase 4) [NCBI Gene 2526] {aka CD15, ELFT, FCT3A, FUC-TIV, FUTIV, LeX}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, TACSTD2 (tumor associated calcium signal transducer 2) [NCBI Gene 4070] {aka EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1}, THY1 (Thy-1 cell surface antigen) [NCBI Gene 7070] {aka CD90, CDw90}
- **Diseases:** primary tumors (MESH:D001932), BCa (MESH:D001943), cancer (MESH:D009369)
- **Chemicals:** glycosphingolipids (MESH:D006028), lipids (MESH:D008055), GSLs (-)
- **Cell lines:** BCa — Homo sapiens (Human), Transformed cell line (CVCL_WC49)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11405820/full.md

---
Source: https://tomesphere.com/paper/PMC11405820